<DOC>
	<DOCNO>NCT00091247</DOCNO>
	<brief_summary>RATIONALE : Tetracycline may effective prevent skin rash cause treatment drug gefitinib cetuximab . PURPOSE : This randomized clinical trial study tetracycline see well work compare placebo prevent skin rash patient receive drug gefitinib cetuximab cancer .</brief_summary>
	<brief_title>Tetracycline Preventing Skin Rash Patients Who Are Receiving Drugs Such Gefitinib Cetuximab Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare 1-month incidence severity gefitinib- , cetuximab- , epidermal growth factor receptor inhibitor-induced skin rash development patient cancer treat tetracycline v placebo . - Compare toxicity drug patient . - Compare quality life patient treat drug develop v develop rash . - Determine whether patient discontinue tetracycline 1 month develop rash . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord prior chemotherapy regimen ( first-line therapy v ) , concurrent epidermal growth factor receptor inhibitor therapy ( gefitinib v cetuximab v ) , concurrent corticosteroid therapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral tetracycline twice daily . - Arm II : Patients receive oral placebo twice daily . In arm , treatment continue 4 week absence unacceptable toxicity . Quality life assess baseline weekly 8 week . Patients follow week 4 8 . PROJECTED ACCRUAL : A total 126 patient accrue study .</detailed_description>
	<mesh_term>Exanthema</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Began therapy within past 7 day plan begin therapy within 7 day study entry one follow epidermal growth factor receptor inhibitor : Gefitinib Cetuximab Erlotinib Monoclonal antibody ABXEGF ICR62 CI1033 EMD72000 No rash study entry PATIENT CHARACTERISTICS : Age 18 Hepatic Bilirubin ≤ 2 mg/dL Renal Creatinine ≤ 2 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception Able take oral medication No history skin condition may flare study treatment No prior allergic reaction severe intolerance tetracycline one derivatives No severe nausea vomit would preclude retain study drug PRIOR CONCURRENT THERAPY : Other More 1 week since prior tetracycline No milk product , antacid , calcium supplement 2 hour 2 hour drug administration No concurrent tetracycline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>